ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) and GT Biopharma (NASDAQ:GTBP – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.
Risk & Volatility
ProMIS Neurosciences has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.
Earnings and Valuation
This table compares ProMIS Neurosciences and GT Biopharma’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProMIS Neurosciences | $10,000.00 | 1,587.12 | -$18.06 million | ($2.60) | -0.71 |
| GT Biopharma | N/A | N/A | -$20.88 million | ($0.46) | -0.53 |
Insider and Institutional Ownership
2.2% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 8.1% of GT Biopharma shares are held by institutional investors. 10.3% of ProMIS Neurosciences shares are held by insiders. Comparatively, 7.0% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares ProMIS Neurosciences and GT Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProMIS Neurosciences | N/A | N/A | -449.60% |
| GT Biopharma | N/A | -144.90% | -100.05% |
Analyst Ratings
This is a summary of current recommendations and price targets for ProMIS Neurosciences and GT Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProMIS Neurosciences | 0 | 0 | 2 | 0 | 3.00 |
| GT Biopharma | 0 | 1 | 1 | 0 | 2.50 |
ProMIS Neurosciences currently has a consensus target price of $8.00, indicating a potential upside of 332.43%. GT Biopharma has a consensus target price of $3.50, indicating a potential upside of 1,327.99%. Given GT Biopharma’s higher possible upside, analysts plainly believe GT Biopharma is more favorable than ProMIS Neurosciences.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
About GT Biopharma
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
